Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
OTLKW was delisted on the 16th of February, 2022.
6 hedge funds and large institutions have $256K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 4 → 6 (+2)
61% less capital invested
Capital invested by funds: $663K → $256K (-$407K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$64K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$416 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $130K | – | – | – |
|
|
SFM
2
Sphera Funds Management
Tel Aviv,
Israel
| $49K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $41K | +$64K | +130,840 | New |
|
|
PC
4
PointState Capital
New York
| $32K | – | – | – |
|
|
CIA
5
Compass Ion Advisors
Conshohocken,
Pennsylvania
| $4K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| – | +$416 | +849 | New |
|
OTLKW Hedge Fund Activity: Q2 2021 in Review
6 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q2 2021, worth a combined $256K — down 61% from $663K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new OTLKW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $64K.
- 6 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q2 2021, up from 4 in Q1 2021.
- Funds reported $256K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q2 2021, down 61% quarter-over-quarter.
- 2 funds opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q2 2021 and 0 closed out, a net change of +2 holders.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 buyer in Q2 2021 was Susquehanna International Group, an estimated $64K added.
Based on aggregated 13F filings for Q2 2021.